Status:

COMPLETED

Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis

Lead Sponsor:

W.L.Gore & Associates

Conditions:

Common Iliac Artery Aneurysms

Aorto-iliac Aneurysms

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

The Iliac Branch Endoprosthesis (IBE) 12-04 study will be a prospective, nonrandomized, multicenter, single-arm evaluation designed to assess the safety and efficacy of the IBE Device in subjects with...

Eligibility Criteria

Inclusion

  • Common iliac aneurysm with or without concomitant abdominal aortic aneurysm
  • Adequate native anatomy to receive the EXCLUDER® and Iliac Branch Endoprostheses
  • An Informed Consent Form signed by Subject or legally authorized representative
  • Male or infertile female
  • Able to comply with protocol requirements including following-up
  • Life expectancy \> 2 years
  • Age \> 21 years
  • Surgical candidate

Exclusion

  • Mycotic or ruptured aneurysm
  • Known concomitant thoracic aortic aneurysm which requires intervention
  • American Society of Anesthesiologists (ASA) Physical Status classification system class V (moribund patient not expected to live 24 hours with or without operation)
  • Renal insufficiency defined or patient undergoing dialysis
  • New York Heart Association (NYHA) Functional Classification class IV
  • Dissected, heavily calcified, or heavily thrombosed landing zone(s)
  • Tortuous or stenotic iliac and/or femoral arteries
  • Participating in another investigational device or drug study within 1 year of treatment
  • Systemic infection which may increase the risk of endovascular graft infection
  • Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome
  • Planned concomitant surgical procedure or major surgery within 30 days of treatment date
  • Known history of drug abuse
  • Known sensitivities or allergies to the device materials

Key Trial Info

Start Date :

October 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2021

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT01883999

Start Date

October 1 2013

End Date

June 1 2021

Last Update

November 2 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Weill Cornell Medical Center

New York, New York, United States, 10065